Weight and Healthcare • 1078 implied HN points • 09 Aug 23
- Novo Nordisk released a press release touting study results that were not peer-reviewed or published, raising ethical concerns.
- The study population in the trial for the weight loss drug Wegovy was limited to specific criteria, excluding certain groups for evaluation of benefits and risks.
- The publicity stunt around the drug's benefits showcases the pharmaceutical company's marketing tactics that may manipulate perceptions and stock prices.